medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 循環器common diseaseの治療を再考する

—心不全治療薬・2—β遮断薬

著者： 長友祐司¹

所属機関： ¹防衛医科大学校循環器内科

ページ範囲：P.80 - P.84

Question 1
心不全に対してのβ遮断薬の有効な使い方を教えてください．

参考文献

1）Engelhardt S, et al：Constitutive activity of the human beta（1）-adrenergic receptor in beta（1）-receptor transgenic mice. Mol Pharmacol 60：712-717, 2001

2）Düngen HD, et al：Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure, The CIBIS-ELD trial. Eur J Heart Fail 13：670-680, 2011

3）Hori M, et al：Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure；Results of the randomized, controlled, double-blind, Multistep Administration of Bisoprolol in Chronic Heart Failure Ⅱ（MAIN-CHF Ⅱ）study. Heart Vessels 29：238-247, 2014

4）Salpeter S, et al：Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD003566, 2005

5）Hori M, et al：Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure；The Multicenter Carvedilol Heart Failure Dose Assessment（MUCHA）trial. Am Heart J 147：324-330, 2004

6）Okamoto H, et al：Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol；Japanese chronic heart failure（J-CHF）study. Int J Cardiol 164：238-244, 2013

7）Böhm M, et al：Heart rate as a risk factor in chronic heart failure（SHIFT）；The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376：886-894, 2010

8）Yoshikawa T, et al：Effectiveness of carvedilol alone versus carvedilol ＋ pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study（KICS）Group. Am J Cardiol 85：1495-1497；a1497, 2000

9）日本循環器学会，他：急性・慢性心不全診療ガイドライン（2017年改訂版）　https://wwwj-circorjp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h_190830pdf, 2017（2020年10月閲覧）

10）Ito H, et al：Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circ J 74：1578-1583, 2010

11）Badve SV, et al：Effects of beta-adrenergic antagonists in patients with chronic kidney disease；A systematic review and meta-analysis. J Am Coll Cardiol 58：1152-1161, 2011

12）Heart Failure Society of America：Evaluation and management of patients with acute decompensated heart failure. J Card Fail 12：e86-e103, 2006

13）Nagatomo Y, et al：Anemia is associated with blunted response to β-blocker therapy using carvedilol；Insights from Japanese Chronic Heart Failure（J-CHF）study. Circ J 82：691-698, 2018

14）Parikh KS, et al：Dose response of β-blockers in adrenergic receptor polymorphism genotypes. Circ Genom Precis Med 11：e002210, 2018

-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol；Japanese Chronic Heart Failure（J-CHF）study. J Card Fail 21：198-207, 2015

16）Kotecha D, et al：Efficacy of β blockers in patients with heart failure plus atrial fibrillation；An individual-patient data meta-analysis. Lancet 384：2235-2243, 2014

17）Nielsen PB, et al：β-blockers in atrial fibrillation patients with or without heart failure；Association with mortality in a nationwide cohort study. Circ Heart Fail 9：e002597, 2016

18）Cadrin-Tourigny J, et al：Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation；An AF-CHF substudy. JACC Heart Fail 5：99-106, 2017

19）Kotecha D, et al：Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 69：2885-2896, 2017

20）Nagatomo Y, et al：Differential response to heart rate reduction by carvedilol in heart failure and reduced ejection fraction between sinus rhythm and atrial fibrillation；Insight from J-CHF study. Cir Rep 2：143-151, 2020

21）Jondeau G, et al：B-CONVINCED；Beta-blocker continuation vs. interruption in patients with congestive heart failure hospitalized for a decompensation episode. Eur Heart J 30：2186-2192, 2009

22）Parameswaran AC, et al：Why do patients fail to receive beta-blockers for chronic heart failure over time? A “real-world”single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure. Am Heart J 149：921-926, 2005

23）Yancy CW, et al：2013 ACCF/AHA guideline for the management of heart failure；A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128：e240-327, 2013

24）McMurray JJ, et al：SC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012；The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association（HFA）of the ESC. Eur Heart J 33：1787-1847, 2012

25）Yamamoto K, et al：Effects of carvedilol on heart failure with preserved ejection fraction；The Japanese diastolic Heart Failure Study（J-DHF）. Eur J Heart Fail 15：110-118, 2013

26）Liu F, et al：Effects of beta-blockers on heart failure with preserved ejection fraction；A meta-analysis. PLoS One 9：e90555, 2014

27）Bavishi C, et al：Beta-blockers in heart failure with preserved ejection fraction；A meta-analysis. Heart Fail Rev 20：193-201, 2015

28）Fukuta H, et al：The effect of beta-blockers on mortality in heart failure with preserved ejection fraction；A meta-analysis of observational cohort and randomized controlled studies. Int J Cardiol 228：4-10, 2017

29）Silverman DN, et al：Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction；A secondary analysis of the TOPCAT Trial. JAMA Netw Open 2：e1916598, 2019

30）Borlaug BA, et al：Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114：2138-2147, 2006

31）Palau P, et al：Beta-blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence；Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial（The Preserve-HR trial）. Clin Cardiol 43：423-429, 2020

32）Nagai T, et al：Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction；A report from the Japanese Heart Failure Syndrome with Preserved Ejection Fraction（JASPER）Registry. Circ J 82：1534-1545, 2018

33）Waagstein F, et al：Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80：551-563, 1989

34）Halliday BP, et al：Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy（TRED-HF）；An open-label, pilot, randomised trial. Lancet 393：61-73, 2019